Detalhe da pesquisa
1.
Hepatocytes direct the formation of a pro-metastatic niche in the liver.
Nature
; 567(7747): 249-252, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842658
2.
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
Br J Cancer
; 122(4): 498-505, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31857726
3.
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Br J Clin Pharmacol
; 86(9): 1836-1848, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32207164
4.
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Br J Cancer
; 120(2): 183-189, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30531832
5.
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Br J Cancer
; 121(5): 429-430, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31350526
6.
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.
Oncology
; 96(4): 217-222, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30844808
7.
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Br J Cancer
; 118(2): 153-161, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28949957
8.
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.
Br J Cancer
; 118(2): e3, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29361630
9.
A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours.
Br J Cancer
; 118(7): 938-946, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29527010
10.
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
N Engl J Med
; 373(5): 428-37, 2015 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-26222558
11.
Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 36(1): 85-95, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28726132
12.
Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
Future Oncol
; 14(6): 553-566, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29460642
13.
Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis.
Cancer
; 123(23): 4680-4686, 2017 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28817187
14.
Clinical study of genomic drivers in pancreatic ductal adenocarcinoma.
Br J Cancer
; 117(4): 572-582, 2017 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28720843
15.
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
N Engl J Med
; 369(18): 1691-703, 2013 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24131140
16.
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
BMC Cancer
; 16: 467, 2016 07 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-27412464
17.
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).
Cancer
; 121(13): 2193-7, 2015 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25827820
18.
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Oncologist
; 20(2): 143-50, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25582141
19.
Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer.
Nanomedicine
; 11(7): 1797-807, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26093057
20.
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727).
Cancer
; 120(19): 2980-5, 2014 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25041791